A Phase 3 interventional study of Denosumab and Zoledronic acid in Cancer, Hematologic Malignancies and Multiple Myeloma, sponsored by Amgen. Completed at 309 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 1,718 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function, as defined by the following criteria (per central or local laboratory values):
Exclusion Criteria:
Evidence of any of the following conditions per subject self-report or medical chart review:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
Drug: Zoledronic acid · Drug: Placebo to Denosumab · Drug: Denosumab (for the open-label treatment phase)
Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
Drug: Denosumab · Drug: Placebo to zoledronic acid · Drug: Denosumab (for the open-label treatment phase)
Administered by subcutaneous injection once every 4 weeks.
Also known as: XGEVA®, AMG 162
Administered by intravenous infusion over 15 minutes once every 4 weeks
Also known as: Zometa®
Administered by subcutaneous injection once every 4 weeks.
Administered by intravenous infusion over 15 minutes once every 4 weeks
Administered by subcutaneous injection once every 4 weeks.
Also known as: XGEVA®, AMG 162
Time to First On-study Skeletal Related Event
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Percentage of Participants With an On-study Skeletal Related Event
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively. The Kaplan-Meier estimate at weeks 25, 49 and 109 is reported.
Time to First On-study Skeletal Related Event - Superiority Analysis
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The average number of events per patient is reported.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The total number of events is reported.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Overall Survival
Overall survival was defined as the time interval (in days) from the randomization date to the date of death. If a participant was still alive at the primary analysis data cut-off date or was lost to follow-up by the primary analysis data cut-off date, survival time was censored at their last contact date or the primary analysis data cut-off date, whichever was first.
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Percentage of Participants Who Died
Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
This study was conducted at 259 centers across 29 countries in Europe, North America, Asia, Australia/New Zealand, and Japan. Participants were enrolled from 17 May 2012 to 29 March 2016.
| Milestone | Zoledronic Acid | Denosumab |
|---|---|---|
| Started | 859 | 859 |
| Received treatment | 852 | 850 |
| Completed | 541 | 555 |
| Not completed | 318 | 304 |
| Withdrew: Death | 147 | 137 |
| Withdrew: Withdrawal by subject | 103 | 112 |
| Withdrew: Completed survival follow-up | 21 | 9 |
| Withdrew: Disease progression | 12 | 10 |
| Withdrew: Adverse event | 6 | 13 |
| Withdrew: Administrative decision | 10 | 8 |
| Withdrew: Noncompliance | 5 | 3 |
| Withdrew: Ineligibility determined | 1 | 6 |
| Withdrew: Protocol deviation | 5 | 0 |
| Withdrew: Other, not specified | 2 | 3 |
| Withdrew: Lost to follow-up | 6 | 3 |
| Milestone | Zoledronic Acid | Denosumab |
|---|---|---|
| Started | 418 | 426 |
| Completed | 227 | 233 |
| Not completed | 191 | 193 |
| Withdrew: Death | 49 | 48 |
| Withdrew: Withdrawal by subject | 49 | 47 |
| Withdrew: Adverse event | 30 | 51 |
| Withdrew: Administrative decision | 30 | 15 |
| Withdrew: Disease progression | 17 | 18 |
| Withdrew: Noncompliance | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Other, not specified | 9 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.
| days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First On-study Skeletal Related Event | 730.0 (504.0 to 1014.0) | 695.0 (448.0 to NA) |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.
| percentage of participants | Zoledronic Acid | Denosumab |
|---|---|---|
| Percentage of Participants With an On-study Skeletal Related Event | 44.6 (41.3 to 47.9) | 43.8 (40.5 to 47.1) |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.
| percentage of participants | Zoledronic Acid | Denosumab |
|---|---|---|
| At Week 25 | 36.5 (33.3 to 39.9) | 35.9 (32.7 to 39.3) |
| At Week 49 | 43.2 (39.7 to 46.8) | 43.7 (40.2 to 47.3) |
| At Week 109 | 50.6 (46.6 to 54.6) | 50.5 (46.6 to 54.5) |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.
| days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First On-study Skeletal Related Event - Superiority Analysis | 730.0 (504.0 to 1014.0) | 695.0 (448.0 to NA) |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The average number of events per patient is reported.
| events/patient | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient | 0.66 | 0.66 |
A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The total number of events is reported.
| skeletal-related events | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First and Subsequent On-Study Skeletal Related Event - Number of Events | 565 | 565 |
Overall survival was defined as the time interval (in days) from the randomization date to the date of death. If a participant was still alive at the primary analysis data cut-off date or was lost to follow-up by the primary analysis data cut-off date, survival time was censored at their last contact date or the primary analysis data cut-off date, whichever was first.
| days | Zoledronic Acid | Denosumab |
|---|---|---|
| Overall Survival | NA (NA to NA) | 1507.0 (NA to NA) |
| percentage of participants | Zoledronic Acid | Denosumab |
|---|---|---|
| Percentage of Participants Who Died | 15.0 (12.6 to 17.4) | 14.1 (11.8 to 16.4) |
Collected over DB (double-blind treatment phase): adverse events (AEs) were from 1st dose of study drug to the later of 30 days after last dose or end of treatment phase. OL (open-label treatment phase): AEs were from 1st dose of OL study drug to end of study. Median months on study drug: 18.4 (zoledronic acid [ZA]) and 19.4 (Denosumab [Dmab]) in DB; 23.2 (ZA/Dmab) and 23.0 (Dmab/Dmab) in OL.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Zoledronic Acid | — | 447/852 (52.5%) | 778/852 (91.3%) |
| DB: Denosumab | — | 434/850 (51.1%) | 757/850 (89.1%) |
| OL: Zoledronic Acid / Denosumab | — | 159/418 (38%) | 313/418 (74.9%) |
| OL: Denosumab / Denosumab | — | 156/426 (36.6%) | 312/426 (73.2%) |
| Event | DB: Zoledronic Acid | DB: Denosumab | OL: Zoledronic Acid / Denosumab | OL: Denosumab / Denosumab |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 82/852 | 79/850 | 34/418 | 31/426 |
| PyrexiaGeneral disorders | 28/852 | 24/850 | 2/418 | 4/426 |
| AnaemiaBlood and lymphatic system disorders | 26/852 | 12/850 | 5/418 | 8/426 |
| Febrile neutropeniaBlood and lymphatic system disorders | 25/852 | 23/850 | 7/418 | 6/426 |
| SepsisInfections and infestations | 24/852 | 19/850 | 8/418 | 11/426 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 13/852 | 18/850 | 11/418 | 12/426 |
| Acute kidney injuryRenal and urinary disorders | 24/852 | 17/850 | 8/418 | 2/426 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 16/852 | 18/850 | 3/418 | 10/426 |
| Respiratory tract infectionInfections and infestations | 8/852 | 7/850 | 8/418 | 5/426 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 13/852 | 16/850 | 5/418 | 3/426 |
| Event | DB: Zoledronic Acid | DB: Denosumab | OL: Zoledronic Acid / Denosumab | OL: Denosumab / Denosumab |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 301/852 | 304/850 | 73/418 | 57/426 |
| NauseaGastrointestinal disorders | 274/852 | 284/850 | 32/418 | 35/426 |
| FatigueGeneral disorders | 215/852 | 206/850 | 43/418 | 38/426 |
| ConstipationGastrointestinal disorders | 214/852 | 207/850 | 19/418 | 27/426 |
| PyrexiaGeneral disorders | 210/852 | 182/850 | 30/418 | 44/426 |
| AnaemiaBlood and lymphatic system disorders | 185/852 | 208/850 | 51/418 | 62/426 |
| Back painMusculoskeletal and connective tissue disorders | 181/852 | 194/850 | 46/418 | 56/426 |
| ThrombocytopeniaBlood and lymphatic system disorders | 151/852 | 174/850 | 27/418 | 27/426 |
| NeutropeniaBlood and lymphatic system disorders | 166/852 | 173/850 | 40/418 | 51/426 |
| CoughRespiratory, thoracic and mediastinal disorders | 170/852 | 159/850 | 51/418 | 47/426 |
| Age, Continuous(years) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Mean | 63.3 ± 10.5 | 63.5 ± 10.6 | 63.4 ± 10.6 |
| Age, Customized(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| < 65 years | 464 | 472 | 936 |
| ≥ 65 years | 395 | 387 | 782 |
| Sex: Female, Male(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Female | 386 | 397 | 783 |
| Male | 473 | 462 | 935 |
| Ethnicity (NIH/OMB)(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 35 | 70 |
| Not Hispanic or Latino | 819 | 823 | 1642 |
| Unknown or Not Reported | 5 | 1 | 6 |
| Race/Ethnicity, Customized(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| White | 699 | 711 | 1410 |
| Asian | 101 | 107 | 208 |
| Black or African American | 36 | 29 | 65 |
| Other | 19 | 10 | 29 |
| American Indian or Alaska Native | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Multiracial | 0 | 1 | 1 |
| Missing | 1 | 0 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| 0 (Fully active) | 259 | 263 | 522 |
| 1 (Restricted but ambulatory) | 413 | 400 | 813 |
| 2 (Ambulatory but unable to work) | 187 | 196 | 383 |
| Skeletal Related Event History(participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Any Skeletal Related Event | 577 | 567 | 1144 |
| Pathological fracture | 463 | 479 | 942 |
| Spinal cord compression | 115 | 92 | 207 |
| Radiation therapy to bone | 139 | 118 | 257 |
| Surgery to bone | 144 | 142 | 286 |
| Summary of Randomization Stratifications(participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Intent to undergo PBSC transplantation: Yes | 465 | 465 | 930 |
| Intent to undergo PBSC transplantation: No | 394 | 394 | 788 |
| Anti-myeloma agent utilized/planned: Novel | 821 | 819 | 1640 |
| Anti-myeloma agent utilized/planned: Non-novel | 38 | 40 | 78 |
| ISS stage at diagnosis: I | 268 | 263 | 531 |
| ISS stage at diagnosis: II | 313 | 319 | 632 |
| ISS stage at diagnosis: III | 278 | 277 | 555 |
| Previous SRE : Yes | 484 | 481 | 965 |
| Previous SRE : No | 375 | 378 | 753 |
| Region: Japan | 18 | 24 | 42 |
| Region: Non-Japan | 841 | 835 | 1676 |
Showing the first 100 of 309 sites across 29 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from May 2012 to primary completion in Jul 2016, 50 months.
Results were first posted in Mar 2018, 1 year 7 months after primary completion. A results delay was requested in Mar 2017.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 50 months is above that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab